Paradigm Clinical Research Featured in KRCR News Redding, CA
Redding-based clinical research center helps combat flu, RSV and COVID-19 by Mike Mangas, Adam Robinson – Monday, October 31st 2022 REDDING, Calif. — A Redding-based clinical research center is helping combat communicable diseases like COVID-19, RSV, and the flu to name just a few. Paradigm Clinical Research was started in Redding in 2009 and now has sites in the San Diego and Denver, Colo. areas, with plans to expand to three more locations in the next year. They enroll volunteers to research the effectiveness of vaccines. “They either receive an RSV vaccine or a placebo. They don’t know; we don’t know. It’s bonded data. Essentially, we draw their blood, we send it to a central lab, and they’re checking antibodies to check to see if the vaccine is efficacious. And we don’t get data of that until after the study ends,” said Sarah Sandberg, the center’s site manager. Volunteers do it for different reasons; there’s a small stipend. But, for someone like registered nurse Dawn Smith, it’s because she’s seen patients die unnecessarily. “I am an RN, and I have observed, participated [in], and witnessed patients who have not been able to, or not educated to, have immunizations. And that gap has caused dire consequences in our community,” Dawn told Mike during an interview on Monday. “I get [that] it’s for the research purposes. Not only does it further the research [on] the last vaccine, which was for COVID-19—that was Moderna. It’s helped out a lot; got the vaccine out to people a lot quicker. And, also, there’s the money factor. It helps out having a little extra money in your pocket,” said Mike Woodward, another research volunteer. Although they have a healthy database, Paradigm is always looking for more volunteers on any number of research projects. “We’re currently doing a flu vaccine study. It’s an mRNA-based flu vaccine for Pfizer. The placebo is the marketed flu vaccine. And that’s 18 and older. We just started enrolling for the full age group today,” Clinical Research Coordinator Emily Crews. Read the full article by KRCR
As Paradigm Clinical Research Expands, So Does the Executive Team
Redding, California – Oct. 6, 2022 — Paradigm Clinical Research, with three dedicated research sites in California and Colorado, announced it has grown its executive leadership team, bringing on board Travis Milnes as chief financial officer (CFO) and Amy Henderson as head of clinical operations. These industry veterans provide additional leadership to Paradigm Clinical Research as the company executes on its plans to expand as a dedicated clinical research business covering a range of therapeutic areas for the biopharmaceutical industry. Travis Milnes, CPA, CFO, is focused on corporate strategy, finance, tax, treasury, information technology, human resources and contracts for Paradigm Clinical Research. He has extensive experience building teams and companies. Previously, at Advarra, Inc., he led the finance department through 11 acquisitions and integrations and four change-of-control transactions and was instrumental in the integration and implementation of standardized processes and procedures for an internationally dispersed team. He began his career as an audit manager with SB & Company, LLC. Amy Henderson, CCRC, head of clinical operations, brings deep experience leading international clinical research teams in highly complex interventional trials. She joined Paradigm Clinical Research from Frenova, the contract clinical research services business of Fresenius Medical Care, where her leadership was instrumental in achieving record-setting productivity, revenue and profitability performance for both Frenova and its partner investigators. At Paradigm Clinical Research, she has an integral role ensuring patient enrollment goals and financial performance objectives are met, as well as growing and managing high-performing sites. Kurt Mussina, who was recently announced as Paradigm Clinical Research’s new CEO, said, “Amy and Travis bring impressive records of success to Paradigm Clinical Research’s executive leadership team. Their experience and subject matter expertise are instrumental to drive our expansion plans not only in terms of additional site locations, but also therapeutic areas and our relationships with principal investigators and the clinical research community in general. I look forward to work with Amy and Travis as we build upon Paradigm Clinical Research’s history of achievement to become a dominant player in the clinical research site market.” About Paradigm Clinical Research Paradigm Clinical Research operates dedicated clinical research facilities with principal investigators actively involved in medical practice and clinical research. Founded in 2009, the company offers clinical trial opportunities to patients and healthy volunteers and provides high-quality study data to the biopharmaceutical industry.
Paradigm Clinical Research Names Industry Veteran Kurt Mussina as CEO as Expansion Plans Are Set in Motion
REDDING, Calif.; Sept. 27, 2022 — Paradigm Clinical Research (Paradigm) announced the appointment of Kurt Mussina as CEO. He will bring more than 30 years of international business success to the clinical research site company, including a record of leadership and achievement structuring and orchestrating global teams in the CRO, CDMO and clinical research site industries. Founded in 2009, Paradigm currently operates three dedicated research sites with two in California and one in Colorado. Paradigm partners with principal investigators who are practicing physicians in a wide variety of medical specialties to execute both healthy volunteer and patient studies. Paradigm has deep expertise that is continuing to grow and a track record of success in neurology, ENT, internal medicine, pulmonology, infectious disease and dermatology, as well as deep experience in vaccine studies. “As the clinical research site landscape evolves, Paradigm is uniquely positioned for growth to become a dominant player in the space,” said Mussina. “Our approach is strategically tailored to addressing the day-to-day demands on our partner investigators, allowing them to participate in clinical trials while also managing successful medical practices. We are intensely fixated on creating and delivering value for all our stakeholders, including partner investigators, study volunteers, sponsors, CROs and our employees. We pride ourselves on delivering as promised, and I look forward to building on Paradigm’s history of achievement.” Before Paradigm, Mussina was president of Frenova, the contract clinical research services company of Fresenius Medical Care (FMC), while also serving as senior vice president in the Global Medical Office of FMC. The business expanded significantly under his leadership to become a network of managed and associated sites, including more than 550 principal investigators across 350 research sites in the U.S. He also led Frenova’s global expansion, leveraging an international network that included over 1,300 clinicians in 45 countries. Paradigm is backed by the private equity firm Crane Street Capital. Managing partner at Crane Street Capital Aleem Choudhry said, “Mussina has decades of experience and leadership with a passion for moving drug development, thus patient care, forward. This will not only help Paradigm to continue growing as a dedicated research business for a wide range of trials for the pharmaceutical industry, but his expertise will also continue to advance clinical research.” About Paradigm Clinical Research Paradigm Clinical Research operates dedicated clinical research facilities with principal investigators actively involved in medical practice and clinical research. Founded in 2009, the company offers clinical trial opportunities to patients and healthy volunteers and provides high-quality study data to the biopharmaceutical industry. About Crane Street Capital Group Crane Street Capital Group specializes in micro growth buyouts in a few selected fragmented industries with untapped white space potential for growth. Its investments target companies that not only have outsized growth potential within their industries but also have the ability to make tremendously positive impacts within the communities in which they operate. Crane Street maintains a concentrated portfolio, deploys capital on an independent basis when outstanding opportunities are available and implements a patient approach in value creation over typically 5+-year holding periods. Currently, there are six companies in the portfolio, three of which are in education services and three of which are in healthcare services.